We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

95 hedge funds and large institutions have $300M invested in Rigel Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 33 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more call options, than puts

Call options by funds: $1.1M | Put options by funds: $531K

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

1% more funds holding

Funds holding: 94 → 95 (+1)

5% more capital invested

Capital invested by funds: $287M → $300M (+$13.2M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 33

Holders
95
Holders Change
+1
Holders Change %
+1.06%
% of All Funds
3.08%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
30
Reduced
33
Closed
12
Calls
$1.1M
Puts
$531K
Net Calls
+$572K
Net Calls Change
+$2.96M

Top Buyers

Rank Fund Capital Flow
1
PAI
Palo Alto Investors
California
+$8.63M
2
Morgan Stanley
Morgan Stanley
New York
+$4.91M
3
Millennium Management
Millennium Management
New York
+$3.97M
4
BC
Broadfin Capital
New York
+$1.88M
5
BBA
Baker Bros. Advisors
New York
+$1.82M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$13.8M
2
State Street
State Street
Massachusetts
-$8.94M
3
DM
Deerfield Management
New York
-$5.99M
4
MG
Meditor Group
Bermuda
-$3.01M
5
TCM
Tekla Capital Management
Massachusetts
-$2.76M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$1.57M -$52.1K -1,427 -3%
TCIM
27
TIAA CREF Investment Management
New York
$1.49M -$337K -9,226 -18%
Geode Capital Management
28
Geode Capital Management
Massachusetts
$1.49M +$217K +5,944 +17%
AQR Capital Management
29
AQR Capital Management
Connecticut
$1.42M -$67.2K -1,840 -4%
FM
30
Forward Management
California
$1.35M +$1.52M +41,520 New
Goldman Sachs
31
Goldman Sachs
New York
$1.23M +$912K +24,989 +268%
AllianceBernstein
32
AllianceBernstein
Tennessee
$1.18M +$6.28K +172 +0.5%
BIM
33
BlackRock Investment Management
Delaware
$1.09M +$8.03K +220 +0.7%
KCM
34
Kennedy Capital Management
Missouri
$927K +$945K +25,904 New
RA
35
Royce & Associates
New York
$881K – – –
Charles Schwab
36
Charles Schwab
California
$823K +$124K +3,386 +17%
SM
37
Sabby Management
Florida
$710K +$724K +19,826 New
BG
38
BlackRock Group
United Kingdom
$595K +$93.7K +2,567 +18%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$562K +$18.3K +501 +3%
RFC
40
Russell Frank Company
Washington
$528K +$301K +8,251 +127%
Jacobs Levy Equity Management
41
Jacobs Levy Equity Management
New Jersey
$486K -$401K -10,989 -45%
MCM
42
Munder Capital Management
Michigan
$482K +$248K +6,800 +102%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$458K -$2.85K -78 -0.6%
USAA
44
United Services Automobile Association
Texas
$435K – – –
TA
45
Teachers Advisors
New York
$424K -$182 -5 -0%
ARTA
46
A.R.T. Advisors
New York
$420K -$370K -10,139 -46%
CS
47
Credit Suisse
Switzerland
$354K -$852K -23,344 -70%
VOYA Investment Management
48
VOYA Investment Management
Georgia
$339K – – –
JP Morgan Chase
49
JP Morgan Chase
New York
$327K +$100K +2,753 +43%
ProShare Advisors
50
ProShare Advisors
Maryland
$308K +$51.2K +1,402 +19%
1
2
3 4 5

RIGL Hedge Fund Activity: Q3 2013 in Review

95 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2013, worth a combined $300M — up 4.6% from $287M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new RIGL positions and 12 closed out — a net gain of 2 holders — while 30 added to existing stakes and 33 trimmed.

The largest buyer was Palo Alto Investors, adding an estimated $8.63M. The largest seller was Wellington Management Group, cutting an estimated $13.8M.

  • 95 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2013, up from 94 in Q2 2013.
  • Funds reported $300M of Rigel Pharmaceuticals stock for Q3 2013, up 4.6% quarter-over-quarter.
  • 14 funds opened new Rigel Pharmaceuticals positions in Q3 2013 and 12 closed out, a net change of +2 holders.
  • The largest Rigel Pharmaceuticals buyer in Q3 2013 was Palo Alto Investors, an estimated $8.63M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2013 was Wellington Management Group, an estimated $13.8M sold.

Based on aggregated 13F filings for Q3 2013.